Search company, investor...
InfraReDx company logo


Founded Year



Corporate Minority | Alive

Total Raised


Last Raised

$25M | 9 yrs ago

About InfraReDx

InfraReDx is a medical device company dedicated to helping provide practitioners with the information needed for enhanced clinical decision making in treating coronary artery disease. The company is committed to improving the safety and efficacy of coronary stenting and ultimately serving as part of a strategy to prevent initial coronary events. Through its TVC Imaging System, InfraReDx is changing the way coronary artery disease is diagnosed and treated. The TVC Imaging System is the only intravascular imaging system that enables true vessel characterization through simultaneous structural and compositional imaging data obtained in a single pullback.

Headquarters Location

34 Third Avenue

Burlington, Massachusetts, 01803,

United States


Missing: InfraReDx's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: InfraReDx's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing InfraReDx

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

InfraReDx is included in 1 Expert Collection, including Medical Devices.


Medical Devices

3,088 items

Companies that have been granted at least 1 510(k) by the FDA since 2014. Companies tagged as #FDA510(K)

InfraReDx Patents

InfraReDx has filed 29 patents.

The 3 most popular patent topics include:

  • Catheters
  • Interventional cardiology
  • Spectroscopy
patents chart

Application Date

Grant Date


Related Topics




Spectroscopy, Catheters, Medical ultrasonography, Medical equipment, Interventional cardiology


Application Date


Grant Date



Related Topics

Spectroscopy, Catheters, Medical ultrasonography, Medical equipment, Interventional cardiology



Latest InfraReDx News

Intravascular Catheters Market Growth Analysis, Latest Trends and Business Opportunities 2022 to 2026

Nov 25, 2022

News Provided By Share This Article Intravascular Catheters Global Market Report 2022 – Market Size, Trends, And Global Forecast 2022-2026 The Business Research Company’s Intravascular Catheters Global Market Report 2022 – Market Size, Trends, And Global Forecast 2022-2026 Avail a limited period discount of 33% on our uniquely designed Opportunities and Strategies market research reports. Contact us today and make winning strategies!” — The Business research company LONDON, GREATER LONDON, UK, November 25, 2022 / / -- Avail a limited period discount of 33% on our uniquely designed Opportunities and Strategies market research reports. Contact us today and make winning strategies! The Business Research Company's "Intravascular Catheters Global Market Report 2022” forecasts the intravascular catheters market is expected to grow from $5.29 billion in 2021 to $5.87 billion in 2022 at a compound annual growth rate (CAGR) of 10.92%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, surge in commodity prices, and supply chain disruptions, effecting many markets across the globe. The intravascular catheters market is expected to grow to $9.15 billion in 2026 at a compound annual growth rate (CAGR) of 11.73%. The rising hospitalization rate owing to the high prevalence of chronic diseases is driving the growth of the intravascular catheters market. Request a Sample now to gain a better understanding of intravascular catheters market: Market Segmentation • By Application: Oncology, Gastroenterology, Renal Disease, Infectious Diseases, Other Applications • By End-Use: Hospitals, Clinics, Ambulatory Surgical Center, Homecare • By Geography: North America, South America, Asia-Pacific, Eastern Europe, Western Europe, Middle East and Africa. Among these regions, North America holds the largest share in the market. Market Size Data • Forecast period: Historical and Future • By region: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa. • By countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. Major market players such as Cook Medical, Smiths Medical, Edwards Life Sciences Corporation, Medtronic Inc, Johnson & Johnson, McKesson Medical Surgical Inc, Terumo Corporation, Abbott Laboratories Inc, Boston Scientific Corp, Getinge AB, Coloplast Corp, Cardinal Health, Conavi Medical, Infraredx Inc, BD, MAQUET Holding BV & Co KG, Vitality Medical, BBraun, Koninklijke Philips NV, Lumend Corporation, Covidien Ag, Acist Medical Systems, Biotronic SE & COKG, Biosense Webster Inc, Cordis, QX Medical and Teleflex Corporated. Trends, opportunities, strategies and so much more. Intravascular Catheters Global Market Report 2022 is one of The Business Research Company’s comprehensive reports that provides in-depth intravascular catheters market research. The market report analyzes intravascular catheters global market overview and intravascular catheters market size, intravascular catheters global market segments, intravascular catheters global market growth drivers, intravascular catheters global market growth across geographies, and intravascular catheters market competitors’ revenues and market positioning. The intravascular catheters global market report enables you to gain insights on opportunities and strategies, as well as identify countries and segments with the highest growth potential. View similar reports by The Business Research Company: Electrophysiology Devices And Equipment Global Market Report 2022

InfraReDx Frequently Asked Questions (FAQ)

  • When was InfraReDx founded?

    InfraReDx was founded in 1998.

  • Where is InfraReDx's headquarters?

    InfraReDx's headquarters is located at 34 Third Avenue, Burlington.

  • What is InfraReDx's latest funding round?

    InfraReDx's latest funding round is Corporate Minority.

  • How much did InfraReDx raise?

    InfraReDx raised a total of $106M.

  • Who are the investors of InfraReDx?

    Investors of InfraReDx include Nipro Corporation, GE Capital, Sanderling Ventures, Epoch Partners, GMP Securities and 4 more.

  • Who are InfraReDx's competitors?

    Competitors of InfraReDx include NeoChord, Reva Medical, Mercator MedSystems, ArraVasc, Stentys and 11 more.

Compare InfraReDx to Competitors

Fox Hollow Technologies

Fox Hollow Technologies, Inc. has developed a coronary catheter that facilitates complete coronary lesion de-bulking, which has been shown to significantly reduce restenosis. The company's technology is designed to address the needs of the interventional cardiologist for a process that has traditionally been complex and has not allowed for complete de-bulking.

Reva Medical

REVA Medical develops interventional medical devices that leverage the company's stent designs and biomaterials to improve the treatment of vascular disease. Its flagship product is called MOTIV, a bioresorbable coronary stent that is designed to fulfill the temporary need for a stent and then fade away, leaving only the healed vessel behind. This product is utilized for the treatment of coronary artery disease. REVA Medical has a broad strategic relationship with Boston Scientific Corporation, a worldwide developer and marketer of interventional medical devices. The company was founded in 1998 and is based in San Diego, California.


Coromedic is a privately owned biomedical start up company working to manufacture devices and develop techniques to facilitate coronary artery bypass surgery in a minimally invasive technique. The company's flagship products, the proximal anastomosis device, the distal anastomosis device and the internal mammary artery harvester are a in a set of invaluable tools aimed at easing the complications associated with the conventional surgery. The company have worked to design and build prototypes of the company's products and develop a business strategy, consulting with numerous professionals to assess the feasibility and utility of the company's product and business model. The process of idea protection and patent application is ongoing, a provisional patent for one of the company's products, the proximal anastomosis devices is in place and the application for patent protection of all the company's products is underway. The prototype of the company's first device, the proximal anastomosis device is built and tested in the wet lab. The company are currently working on prototype assembly of the company's second and third products, after which lab animal experiments in the appropriate facilities will take place and then approval for clinical trials and their undertaking will commence.

Tryton Medical Logo
Tryton Medical

Tryton Medical is a developer of stent systems for the treatment of bifurcation lesions. The Tryton Side Branch Stent System is built for bifurcation using Tri-ZONE technology to offer a dedicated strategy for treating bifurcation lesions. Tryton's cobalt chromium stent is deployed in the side branch artery using a standard single-wire balloon-expandable stent delivery system. A conventional drug-eluting stent is then placed in the main vessel. The stent system has received CE Mark and is commercially available throughout Europe, Russia and the Middle East. It is approved in the United States for investigational use only.

Endologix Logo

Endologix is a developer and manufacturer of minimally invasive treatments for vascular diseases. Endologix is focusing on the development and marketing of its patented technology for the treatment of Abdominal Aortic Aneurysms (AAA). An aneurysm is a weakening of the wall of the aorta, the largest artery of the body. Aortic aneurysm disease is a cause of death in the United States and it is estimated that 1.7 million persons over 55 years of age have an AAA. Each year, physicians diagnose approximately 200,000 people in the United States with AAA. Endologix is currently marketing its Powerlink Delivery System a, one-piece endoluminal stent graft (ELG) used in treating AAA that has significant advantages when compared with marketed stent alternatives. Powerlink has been commercially available in Europe since 1999. FDA approval for the Powerlink AAA stent graft was received on October 29, 2004. The Powerlink superior design is covered by 17 U.S. patents with 361 allowed claims; the technology is designed to overcome shortcomings of first-generation ELGs. The device is for sale in the United States and selected international markets. Endologix is a publicly-held company trading on NASDAQ: ELGX. The company's corporate office is located in Irvine, California.

Intella Interventional Systems

Stent systems develops angioplasty catheters and guidewires, and related interventional products

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.